- Home
- BGI vs APVO Comparison
BGI vs APVO Comparison
Compare BGI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- APVO
- Stock Information
- Founded
- BGI 1879
- APVO 2016
- Country
- BGI Canada
- APVO United States
- Employees
- BGI N/A
- APVO N/A
- Industry
- BGI
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- APVO Health Care
- Exchange
- BGI Nasdaq
- APVO Nasdaq
- Market Cap
- BGI 22.7M
- APVO 21.7M
- IPO Year
- BGI 2005
- APVO N/A
- Fundamental
- Price
- BGI $1.09
- APVO $1.48
- Analyst Decision
- BGI
- APVO
- Analyst Count
- BGI 0
- APVO 0
- Target Price
- BGI N/A
- APVO N/A
- AVG Volume (30 Days)
- BGI 47.9K
- APVO 990.5K
- Earning Date
- BGI 11-26-2025
- APVO 11-06-2025
- Dividend Yield
- BGI N/A
- APVO N/A
- EPS Growth
- BGI N/A
- APVO N/A
- EPS
- BGI N/A
- APVO N/A
- Revenue
- BGI $124,446,731.00
- APVO N/A
- Revenue This Year
- BGI N/A
- APVO N/A
- Revenue Next Year
- BGI N/A
- APVO N/A
- P/E Ratio
- BGI N/A
- APVO N/A
- Revenue Growth
- BGI N/A
- APVO N/A
- 52 Week Low
- BGI $0.56
- APVO $1.32
- 52 Week High
- BGI $2.20
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- BGI 46.14
- APVO 46.10
- Support Level
- BGI $1.13
- APVO $1.40
- Resistance Level
- BGI $1.14
- APVO $1.53
- Average True Range (ATR)
- BGI 0.05
- APVO 0.08
- MACD
- BGI -0.02
- APVO 0.01
- Stochastic Oscillator
- BGI 12.56
- APVO 38.64
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.